Loading
A phase 2 trial of Cadonilimab, Ivonescimab in ovarian cancer, run by Akeso, now recruiting.
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06560112 by Akeso, with 172 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-05-01. Interventions recorded: AK104, AK112, Chemotherapy. Conditions listed: Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors.